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One of the possible courses of cancer treatment is teletherapy, and one of the most important 
adverse side effects are skin reactions, an ailment more commonly called radiodermatitis. The 
main purpose of this study is to analyze knowledge of the evidence about topical products used 
in the prevention of radiodermatitis, to support care delivery to women with breast cancer 
during teletherapy. The research method used here is the comprehensive literature review. Four 
databases were used to select the bibliography. The sample consists of 15 articles. The data 
shows that, among the topical products analyzed here, Calendula, corticosteroids and Xclair have 
shown significant protective effects, underlining their actions. The lack of articles published in 
Brazil highlights the need for further research in this area, seeking better care quality through 
the use of products with scientifically proven efficiency.
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Prevenção de reações de pele devido à teleterapia em mulheres com 
câncer de mama: revisão integrativa
Dentre as modalidades de tratamento para o câncer está a teleterapia, e um dos principais 
efeitos adversos dessa modalidade são as reações de pele, comumente chamadas 
radiodermatites. O presente estudo teve como objetivo analisar o conhecimento sobre 
as evidências acerca de produtos tópicos, utilizados na prevenção de radiodermatite, que 
fundamente o cuidado em teleterapia direcionado a mulheres com câncer de mama. Adotou-
se como método de pesquisa a revisão integrativa da literatura. Para a seleção da bibliografia 
utilizaram-se quatro bases de dados. A amostra constitui-se de 15 artigos. Os dados 
demonstram que, dentre os produtos tópicos analisados, a calêndula, os corticoesteroides 
e o Xclair tiveram efeito protetor significante, destacando-se, assim, pelas suas ações. A 
ausência de artigos publicados no Brasil mostra a necessidade de mais pesquisas nessa 
área, visando a melhor qualidade na assistência a mulheres com câncer de mama, por meio 
da utilização de produtos com eficácia comprovada cientificamente.
Descritores: Radiodermatite; Radioterapia; Neoplasias da Mama.
Prevención de las reacciones en la piel debido a teleterapia en mujeres 
con cáncer de mama: revisión integradora
Teleterapia está entre las modalidades de tratamiento para el cáncer y uno de sus principales 
efectos adversos son reacciones de la piel, comúnmente llamado radiodermatitis. Este 
estudio objetivó analizar el conocimiento acerca de los productos tópicos utilizados para 
la prevención de la radiodermatitis que justifiquen la atención en teleterapia en mujeres 
con cáncer de mama. Se adoptó como método de investigación la revisión integradora 
de la literatura. Para la selección de los artículos se utilizaron cuatro bases de datos. La 
muestra fue constituida por 15 artículos. Los datos muestran que entre los productos 
tópicos analizados la caléndula, esteroides y Clair X tuvo un efecto protector significativo, 
destacando así por sus acciones. La ausencia de artículos publicados en Brasil se centra en 
la necesidad de seguir investigando para mejorar la calidad de la atención mediante el uso 
de productos con una eficacia científicamente probada.
Descriptores: Radiodermatitis; Radioterapia; Neoplasias de la Mama.
Introduction
One of the treatment courses for breast cancer 
is teletherapy, which makes use of ionising radiation. 
This damages the cell components, with DNA as the 
main target. Radiotherapy brings about changes or 
even mutations to the genetic material, and also leads 
to changes in cell function, until the death of the cell. 
Thus, ionising radiation causes damage to all living and 
normal cells, as well as malignant ones, thereby causing 
side effects(1).
Among local toxic effects, cutaneous reactions 
are highlighted, known as radiodermatitis: erythema, 
hyperpigmentation, dry scaling and moist scaling. What 
characterizes the latter is the exposure of the dermis and 
seepage of fluid, sometimes accompanied by exudate and 
crust or ulceration, or even necrosis(2-3).
The degree of skin reaction depends on several 
factors, such as: irradiation in places where there is 
contact between surfaces, areas where the epidermis 
is thin or where skin integrity has been ruptured, 
like in the case of burns, concurrent chemotherapy, 
immunotherapy, associated medical conditions or 
co-morbidity, chronic exposure to the sun, smoking, 
localization of the tumor or field treated, tumor staging, 
large irradiated volume, high dose of total radiation, 
dose with a fraction of more than 2.0 Gy, and the type 
of energy used(2-3).
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In about 80% of the patients, radiation leads to 
dermatitis, varying in severity from moderate to severe 
erythema and moist scaling. The consequences are many, 
including decreased quality of life due to pain and interruption 
of treatment, which can be harmful for local control(4).
Several studies have been conducted to assess the 
results of preventive interventions, and the management 
of skin reactions caused by radiotherapy. There is a 
continuous lack of evidence to recommend many courses 
of intervention or products used in clinical practice though. 
Studies focus on prevention more than management, and 
are wanting in methodological rigor, making it difficult 
to repair studies with a view to elaborating specific 
recommendations. Other methodology problems include 
small sample size, wide variety in the terms used to 
describe reactions and measurement tools(3).
Considering that radiodermatitis tends to occur 
quite often and harms the quality of life of radiotherapy 
patients, and also the lack of consensus about the topical 
products used in prevention, the main purpose of this 
study is to analyze knowledge on the topical products 
used in the prevention of radiodermatitis, with a view to 
supporting care delivery to women with breast cancer 
during teletherapy.
Methodological Procedures
For the development of this study, Evidence-Based 
Practice (EBP) was adopted as the theoretical and 
methodological framework. A comprehensive literature 
review was chosen. This method permits the analysis and 
synthesis of multiple published studies on a certain subject, 
as well as the identification of gaps that need to be filled 
through new research, and also general conclusions about 
a particular study area, with the resulting incorporation 
of the best and most recent evidence for decision making 
and improvement of clinical practice(5-6).
The preparation of the comprehensive review occurred 
in six stages: identification of the theme and selection of 
the hypothesis or research question, establishment of 
criteria for inclusion and exclusion of studies, sampling 
or search in the literature, definition of the information to 
be extracted from the selected studies, assessment of the 
studies included in the review, interpretation of the results 
and synthesis of knowledge(6).
The guiding question for this review was: What 
scientific knowledge has been produced on topical products 
used in the prevention of radiodermatitis in women with 
breast cancer and subject to teletherapy?
For the selection of the bibliography, four different 
databases were used: MEDLINE (Medical Literature 
Analysis and Retrieval System Online), specifically 
PubMed, LILACS (Latin American and Caribbean Centre 
on Health Sciences Information - Literatura Latino-
Americana e do Caribe em Ciências da Saúde), CINAHL 
(Cumulative Index to Nursing and Allied Health Literature) 
and the Web of Science, which is a set of databases 
(Science Citation Index, Social Science Citation Index, 
Arts and Humanities Citation Index, Current Chemical 
Reactions and Index Chemicus). Figure 1 displays the 
descriptors used in all the databases.
The criteria for inclusion as adopted to select the 
articles were: fully available; written in Portuguese, 
English or Spanish between January 2000 and July 2010; 
a central theme based on topical products used in the 
prevention of radiodermatitis in women with breast cancer 
who have been subject to teletherapy.
A pre-selection was made, comprising 20 references 
in CINAHL, 16 in Web of Science, 97 in PubMed and 14 in 
LILACS. Through the reading of the title and abstract, we 
identified 15 articles that met the previously established 
inclusion criteria and addressed the guiding question, and 
were therefore part of the final sample.
In possession of the articles, each was exposed 
to exploratory reading. With a view to establishing 
categories and assess the studies, with the consequent 
interpretation of results, an instrument was used 
with the following items: identification, the institution 
where the study was conducted, the type of scientific 
publication, the methodological characterization of the 
study and the assessment of methodological rigor(7). 
Concepts nursing researchers proposed were used to 
set limits for the review(8).
Concerning the identification of the selected papers’ 
level of evidence, the following classification was used: 
level 1 – evidence from systematic review or meta-analysis 
of all relevant clinical trials, randomized and controlled, or 
arising from clinical guidelines based on systematic review 
of randomized controlled clinical trials; level 2 – evidence 
derived from at least one randomized well-defined clinical 
Database Controlled Descriptors
Uncontrolled 
Descriptors
MEDLINE/ PUBMED
Breast neoplasms 
and therapeutics 
and radiodermatitis
LILACS
Radiodermatitis
Radiodermatitis and 
breast neoplasms
CINAHL Radiodermatitis and breast neoplasms
Web of Science
Radiodermatitis and 
breast cancer or breast 
neoplasms
Figure 1 – Descriptors used according to the database
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trial; level 3 – evidence obtained from well-defined clinical 
trials without randomization; level 5 – evidence arising from 
the systematic review of descriptive and qualitative studies; 
level 6 – evidence derived from one single descriptive or 
qualitative study; level 7 – evidence arising from opinions 
of authorities and/or reports from experts committees(9).
Data were analyzed descriptively, permitting 
professionals to assess the quality of evidence about the 
research theme, thus supporting decision-making and 
the identification of knowledge gaps with a view to future 
research.
Results
The analysis of the 15 articles selected showed that, 
in five cases, the authors were nursing researchers, mostly 
in partnership with physicians from several different 
specialties. All were published in international journals 
and in English. l Research originated in several countries: 
the United States (3), Australia (2), India (2), Canada (1), 
France (1), Sweden (1), Germany (1), Israel (1), Spain 
(1) and Italy (1). In one case, the country of origin could 
not be established.
As for the studies’ methods, thirteen articles had a 
quantitative approach, twelve being experimental studies 
(randomized controlled clinical trials) with evidence level 
2 and one quasi-experimental study (Phase II clinical trial 
without randomization), with evidence level 3, considering 
strong evidence levels according to the classification used. 
One article was a narrative review of the literature and, as 
such, did not have an evidence level. The final article was 
a cohort study with evidence level 4.
Figures 2, 3 and 4 present a summary of the articles 
analyzed.
Study Aim Results Conclusions
Schmuth et al.(10)
Randomized controlled 
clinical trial (n= 36).
To compare the efficiency 
of Dexapantenol with 
corticosteroids applied in 
patients with breast cancer 
and subject to radiotherapy 
(RT). 
Comparisons of average severity scores between 
groups as treated suggest that clinical progress 
is less severe among patients who received 
Methylprednisalone compared to those who 
received Dexapantenol. The comparison between 
the intervention and control groups suggests that 
one of the two topical treatments produces better 
results than no treatment, but the difference was 
not statistically significant. (p > 0.05). 
The data suggests that topical 
treatment is better than no treatment, 
and corticosteroids seem to be more 
effective than Dexapantenol alone.
Enomoto et al.(11)
Randomized controlled 
clinical trial (n= 32).
Appraise the efficiency of Ray 
Gel as a skin protector.
The average severity score for skin reactions 
was lower in the RayGel group (93.7) than in the 
placebo group (123).
Ray Gel showed a tendency to be 
better than the placebo, but did not 
achieve statistical significance due to 
the sample size .
Shukla et al.(12)
Randomized controlled 
clinical trial (n= 60).
Observe the difference in the 
occurrence of moist scaling in 
the underarm region with the 
use of Beclometasone Spray.
In the steroidal group, four patients (13.33%), and 
11 (36.66%) in the control group, showed moist 
scaling in the underarm region after a dose of 50 
Gy ( p= 0.0369). 
The study shows a significant reduction 
in the risk of moist scaling with the use 
of topical steroids, and this should be 
recommended for the start of RT with 
maximum effect.
Fisher et al.(13)
Randomized controlled 
clinical trial (n= 185).
Compare Biafine with the 
best standard care for the 
prevention of radiodermatitis.
There was no difference in relation to maximum 
toxicity, grade 2 toxicity or duration of radiodermatitis 
between the patients treated with Aloe Vera, Biafine 
and the standard care during RT. 
This study was unable to support the 
hypothesis that Biafine is more effective 
than standard care for the prevention of 
radiodermatitis.
Graham et al.(14)
Randomized controlled 
clinical trial (n= 61).
Test the prophylactic effect 
of Cavilon 3M no-sting 
barrier film on the rates of 
moist scaling, compared with 
Sorbolone cream (glycerine 
10 %). 
No significant evidence was found in relation to 
the values of pain or the need for analgesia. For 
all patients, the average skin toxicity score was 
8.1 in the case of No-Sting and 9.2 for Sorbolone, 
respectively (p= 0.005). The rate of moist scaling 
was 33% in the case of No-Sting, compared with 
46% (Sorbolone), with p= 0.096. 
The study suggests that the film is 
better than Sorbolone, but it may not 
be better than prophylactic skin care . 
No-Sting film reduced the duration and 
frequency of radiation-induced moist 
scaling.
Pommier et al.(4)
Randomised controlled 
clinical trial (n= 254).
Assess the efficiency of 
Calendula in the prevention 
of Grade 2 radiodermatitis or 
worse during RT for breast 
cancer, when compared with 
Trolamine.
Incidence of acute skin toxicity of grades 2 
and 3 was 41% in the Calendula group and 
63% for the Trolamine group (p=0.001). No 
Grade 4 toxicity was observed. Adherence to 
the application of the ointment was considered 
satisfactory by 84% of the patients of the 
Calendula group and 92% of the Trolamine 
group.
Calendula is highly effective in the 
prevention of acute dermatitis of Grade 
2 of higher, and shall be proposed 
as preventive treatment for patients 
subject to RT for breast cancer.
Roper et al.(15)
Randomised controlled 
clinical trial (n= 20).
Assess the efficiency of Tetra-
Cream when compared with 
Bepantol in the prevention of 
radiodermatitis.
There was no significant trend in favour of Bepantol 
with a total average value of 8 compared to 11 for 
Tetra-Cream (p = 0.17). There was no statistical 
difference for the maximum value of each aspect 
of skin toxicity for both groups at levels of 30 Gy 
and 50 Gy. The patients have shown a high level 
of satisfaction with the regime of care within both 
groups.
It was not possible to show any 
advantages to the use of Tetra-Cream 
compared with Bepantol in skin 
care for patients subject to RT. The 
physiopathology of radiodermatitis 
needs to be studied to promote 
therapeutic strategies.
(The Figure 2 continue in the next page)
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Study Aim Synthesis
Aistars(2)
Narrative literature review .
Analyze research on skin care during 
radiation, specifically concerning 
prevention and managementof 
erythema and dry scaling, between 
1996 and June 2005.
No difference was found between skin care products in the prevention of skin 
toxicity in controlled and randomized clinical studies; the instrument known 
as STAT (Skin Toxicity Assessment Tool) is valid and reliable as a measure of 
radiation-induced skin toxicity.
Figure 4 – Synthesis of narrative literature review
Study Aim Results Conclusions
Masferrer et al.(22)
Cohort Study
Assess the efficiency of the 
intensive use of a lotion 
containing 3% urea, polydocanol 
and hyaluronic acid to 
prevent the onset of acute 
radiodermatitis, and also control 
its severity.
Compared with the subgroup of controls that 
had used the lotion under normal conditions, the 
intensive use group had lower rates of occurrence 
of radiodermatitis (72.4% VS 100%, p<0.01), lower 
toxicity (p <0.001) and also lower proportions of 
radiodermatitis of Grade 2 or higher (21.4% vs. 
50%, p<0.01). The physicians and patients classify 
efficiency, tolerability and cosmetic properties of the 
lotion as good or excellent.
The data show that the intensive use 
of the lotion doubles the likelihood that 
patients with breast cancer will not 
develop radiodermatitis during RT, and 
also halves the risk of developing toxicity 
of Grade 2 or above. Both physicians and 
patients associate it with good tolerability  
and acceptance.
Figure 3 – Synthesis of research with non-experimental definition.
Heggie et al.(16)
Randomised controlled 
clinical trial (n= 225).
Test the hypothesis that 
topically applied Aloe Vera 
was effective in reducing the 
dermatological side effects 
of RT when compared with 
aqueous cream.
The Kruskall-Wallis test was not significant for the 
worst grades of seepage, pain and moist scaling 
between the two groups. Regarding the worst 
grade of dry scaling, it was statistically significant 
for the Aloe Vera group having greater duration 
and prevalence of such toxicity compared to 
the Aqueous group (p=0.004). There was no 
statistical difference between the groups in terms 
of cumulative probability, prevalence and duration 
of the erythema.
Based on the study findings, Aqueous 
Cream or a similar moisturizing agent 
is recommended for use on the skin 
during RT. Aloe Vera gel can be 
beneficial when used together with 
Aqueous Cream.
Bostrom et al.(17)
Randomised controlled 
clinical trial (n=50).
Establish whether 
Mometasone Fuorate (a 
corticosteroid), used in 
prophylaxis and treatment, 
can reduce the intensity 
of the erythema in acute 
radiodermatitis.
The rate of total erythema in patients was 
significantly lower in the Mometasone Fuorate 
(MMF) group compared with the group treated 
only with Emollient (p=0.0033). The patients in 
the MMF group have experienced less seepage 
and burning than the Emollient group, but the 
difference was not statistically significant. No 
difference in relation to pain was found (p=0.42).
The results of this study support 
the moderate use of corticosteroids 
in topical form, from the first day of 
radiotherapy through to 3 weeks 
after the end of the treatment, 
as a prophylactic agent against 
radiodermatitis.
Omidvari et al.(18)
Randomised controlled 
clinical trial (n= 68).
Assess the prophylactic effect 
of 0.1% topical Betametasone 
on radiodermatitis (ARD).
End of 3rd week: 26.3% of the Betametasone 
Group developed Grade I dermatitis, compared 
with 64.7% and 66.7% of the emollient group and 
control group, respectively, with a statistically 
significant difference (p=0.027). At the end of the 
7th week, 15.8% of the Betametasone group had 
Grade 1 dermatitis, while the control group had 
6.7% of such cases. Even though the patients 
who received Betametasone had lower grades 
of radiodermatitis than the other two groups, this 
difference was not significant (p=0.055).
The study supports the prophylactic use 
of Betametasone at 0.1% to prevent or 
improve ARD. No effect of Petrolatum 
(Vaseline) on the prevention of ARD 
was found.
Szumacher et al.(19)
Non-randomised clinical 
trial (n = 60).
Assess the efficiency of Biafine 
cream as a prophylactic agent 
for radiation-induced acute 
skin toxicity in women subject 
to RT and chemotherapy for 
breast cancer.
During the RT: toxicity less than Grade 2, 15%; 
Grade 2 toxicity, 83%; Grade 3 toxicity, 2%; Grade 
4 toxicity, no patients. For a period of four weeks 
after RT, the highest skin reaction scores recorded 
were: Grade 0, 15%; Grade 1, 44%; Grade 2, 
34%; Grade 3, 6%. In the fourth week after RT, 
the skin reaction scores for 42 patients with 
available data were: 83% had a Grade less than 2 
and 17% had Grade 2 radiodermatitis.
Most patients subject to QT and 
simultaneous RT for breast cancer 
developed Grade 2 radiodermatitis with 
the use of Biafine cream. However, no 
interruption or extension to the duration 
of the treatment was observed as a 
result of skin toxicity.
Fenig et al.(20)
Randomised controlled 
clinical trial (n= 74).
Assess the efficiency of Biafine 
and Lipiderm in the prevention 
of radiodermatitis.
The analysis of the efficiency of the treatment did not 
show any advantages when the three groups were 
compared. However, 19 patients (86%) in the Biafine 
group and 18% (85%) of the Lipiderm group showed 
some degree of satisfaction with the treatment.
No beneficial effects were shown for 
either Biafine or Lipiderm, both widely 
used in clinical practice to prevent 
radiodermatitis.
Primavera et al.(21)
Randomised controlled 
clinical trial (n= 20).
Assess the efficiency 
of MAS065D (Xclair) in 
radiodermatitis in patients 
subject to radiotherapy for 
breast cancer.
Xclair showed significant benefits compared to the 
product used in the control group, in relation to all 
grades of skin reactions on the fifth visit and also 
for erythema on the fifth and the seventh visits. 
No significant difference was found in relation to 
pain and seepage, comparing the two groups. In 
relation to patient preference, 65% preferred Xclair, 
while 10% prepared the control product.
The results show a general reduction in 
and delayed onset of radiodermatitis. 
We can conclude that MAS065D 
caused an ideal effect for the 
management of skin reactions.
Figure 2 – Synthesis of research with experimental and quasi-experimental definition.
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Discussion
Through an analysis of the selected publications, 
we identified a wide range of products used to 
prevent radiodermatitis in women with breast cancer 
during radiotherapy, such as covers based on topical 
corticosteroids, Biafine, Calendula, Tetra-Cream®, 
Bepantol®, Aloe Vera, and others.
Some studies show controversy about the efficiency of 
using topical corticosteroids in radiodermatitis treatment. 
In initial trials, the use of less potent corticosteroids, 
variations in the location and also the period to start the 
application, patients’ heterogeneity in terms of cancer 
types, doses, regimens and application region of of 
radiotherapy and subjective analysis methods suggest 
that there is a lack of preventive effect for this substance. 
However, in the studies analyzed, we observed a clinical 
reduction in the severity of the symptoms shown, less 
damage to the skin permeability barrier and improvement 
of inflammatory response, resulting from the radiation-
induced rupture of the barrier, as well as the significant 
reduction in the risk of developing moist scaling in patients 
using corticosteroids compared with those using other 
products(10,12,17-18).
According to the results shown, treatment with 
steroids should start together with the start of radiotherapy, 
for maximum effect. The importance of applications from 
the start of treatment is due to the fact that skin toxicity 
signs caused by radiotherapy may occur soon after the 
first dose of radiation(12,17).
The protective effect of corticosteroids could be 
linked to their anti-inflammatory properties. Short-term 
observations have not shown any increase in the rate of 
telangiectasias, skin atrophy or the risk of suppression of 
the axis formed by the pituitary and adrenal glands. These 
factors limit their long-term use (18).
Among the products analyzed, Betamesanone 0.1%, 
Mometasone Fuorate and Beclometasone spray were the 
products that showed the best results and are also the 
most recommended for prophylactic use in the prevention 
of this co-morbidity.
However, the results of these research studies 
(10,12,17) should be used with care, as some studies have 
methodology problems that could put the findings at 
risk, such as non-homogeneity and reduced sample size, 
loss of patients during follow-up, lack of blinding, lack 
of control of the main confounding factors and lack of a 
control group. New studies with greater methodological 
strictness are necessary to confirm these findings.
Another agent that has shown efficiency in the 
prevention of radiodermatitis during RT in women with 
breast cancer is Calendula. Through the results of the 
study, we have seen that this cover was statistically better 
in the prevention of Cutaneous toxicity of Grade 2 or higher. 
The clinical relevance of this result is stressed through 
the significant improvement in self-assessed pain-related 
patient satisfaction, low levels of allergies and treatment 
interruption, except for the facility of application, as the 
patients consider this difficult to apply (4).
MAS065D (Xclair), which is a compound of 
hyaluronic acid, vitis vinifera, karité butter, telsmetine, 
glycyrrhizic acid and bisabolol in a hydrolipidic medium 
has also shown a protective effect in relation to skin 
toxicity due to radiotherapy. The main aim of this 
product is to reduce inflammatory reactions and keep 
a moist environment in the affected surface. Hyaluronic 
Acid (HA) is a natural biopolymer with a high capacity 
to retain water. It is the most important element of the 
extracellular unit of dermal tissue, providing mechanical 
and structural support. Clinical trials with the topical 
application of HA have shown improvement in wound 
cleaning, particularly in cases of radioepithelites, due 
to its notable rheological (viscosity), viscoelastic and 
hygroscopic properties (absorption of water), which are 
relevant in the healing process(21-22).
Vitis vinifera and telmestine antiprotease have 
antioxidant properties that are able to inhibit harmful 
enzymes present in the exudate of the damaged skin 
and also protect the tissue from the damage free radicals 
cause. Another key substance that is present in Xclair 
is glycyrrhizic acid (liquorice root), which has anti-
inflammatory properties. In the case of karité butter, 
extracted from Parkii butyrospermum, it is used for its 
emollient action(21).
The results of the study show a global reduction in 
skin reaction due to radiation, as well as a delay in its 
appearance. It could also be concluded that Xclair provides 
an efficient option for radiodermatitis management. 
Treatment efficiency concerning pain and seepage should 
be considered in further research, involving groups of 
patients with specific characteristics(21).
Final Comments
According to the surveys analyzed, to prevent 
radiodermatitis due to RT in women with breast cancer, 
the most recommended products for topical use, according 
to the level of evidence and the methodological definition 
of the studies, are topical corticosteroids, Calendula and 
MAS065D (Xclair), which can therefore be incorporated 
into clinical practice.
The studies suggest, as an indication for the use 
of these products, uniform application, starting at the 
same time as the start of RT, twice a day or more often, 
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depending on the occurrence of dermatitis and pain, until 
the treatment is completed or continuing for another two 
weeks after the end of treatment. In the case of Calendula, 
the restriction on use within 2 hours of the RT session 
should also be mentioned.
Radiodermatitis is an important side effect, due to 
its high rate of occurrence among patients submitted to 
teletherapy. It should be mentioned here that studies with 
a better methodological definition are needed to prove or 
reject these study findings. In addition, the lack of articles 
published in Brazil suggests the need for further research 
in this area, in order to establish protocol procedures for 
care related to prevention and appropriate management 
of the lesions, which institutions in search of better care 
quality can follow. The researchers hope that, through this 
study, interest on this subject in general will be enhanced.
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